Liver Metastases of Colorectal Cancer: Medical Treatments

Anticancer Research

Volumn 23, Issue 5 B, 2003, Pages 4245-4256

  Pasetto, Lara Maria ^a   Rossi, Elena ^a   Monfardini, Silvio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; Liver metastases; Review

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; METHOTREXATE; OXALIPLATIN; RALTITREXED; TEGAFUR; UFT;

ADJUVANT CHEMOTHERAPY; ALOPECIA; ASTHENIA; BLOOD TOXICITY; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERABILITY; DRUG TOXICITY; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER METASTASIS; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEPSIS; SIDE EFFECT; STOMATITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS;

EID: 0345303862     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Berinan RS, Portera CA and EIlis LM: Biology of liver metastases. Cancer Treat Rev 109: 183-206, 2001.
2. Malafosse R, Penna Ch, Sa Cunha A and Nordlinger B: Surgical management of hepatic metastasis from colorectal malignancies. Ann Oncol 12 (7): 887-894, 2001.
3. Vogl TJ, Muller PK, Mack MG, Straub R, Engelmann K and Neuhaus P: Liver metastases: interventional therapeutic techniques and results, state of the art. Radiol 9 (4): 675-684, 1999.
4. Jamison RL, Donohue JH, Nagorney DM, Rosen CB et al: Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 132: 505-511, 1997.
5. Lorenz M, Muller H, Schramm H et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 228: 756-764, 1998.
6. Langer B, Bleiberg H, Labianca R, Shepherd L et al: Fluorouracil (FU) plus 1-leucovorin (1-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Am Soc Clin Oncol 21: 149 (abs 592), 2002.
7. Portier G, Rougier P, Milan C, Bouchè O et al: Adjuvant systemic chemotherapy (CT) using 5-fluorouracil and folinic acid after resection of liver metastases (LM) from colorectal cancer (CRC) origin. Am Soc Clin Oncol 21: 133 (abs 528), 2002.
8. De Gramont A, Bosset JF, Milan C, Rougier P et al: Randomized trial comparing monthly low-dose leucovorin and 5-fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J Clin Oncol 15 (2): 808-815, 1997.
9. Hoff PM, Ansari R, Batist G, Cox J et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19 (8): 2282-2292, 2001.
10. Streit M, Jaehde U, Stremetzne S, Ridwelski K et al: Five days continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen. Ann Oncol 8 (11): 163-165, 1997.
11. Hartmann JT, Kohne CH, Schmoll HJ, Daikeler T, Kanz L and Bokemeyer C: Is continuous 24-hour infusion of 5-fluorouracil plus high dose folinic-acid effective in patients with progressive or recurrent colorectal cancer? A phase II study. Oncology 55 (4): 320-325, 1998.
12. Erlichman C, Fine Sm, Wong A and Elhakim T: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6 (3): 469-475, 1988.
13. Aranda E, Cervantes A, Dorta J, Blanco E et al: A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Cancer 76 (4): 559-563, 1995.
14. Machover D: A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer 80 (7): 1179-1187, 1997.
15. Ychou M, Fabbro-Peray P, Perney P, Marcais O et al: A prospective randomized study comparing high- and low-dose leucovorin combined with the same-dose 5-fluorouracil in advanced colorectal cancer. Am J Clin Oncol 27 (3): 233-236, 1998.
16. Romero AO, Perez JE, Cuevas MA, Lacava JA et al: Double modulation of 5-fluorouracil by methotrexate and high dose L-leucovorin in advanced colorectal cancer. Am J Clin Oncol 21 (1): 94-98, 1998.
17. Kohne CH, Cunnigham D, Di Costanzo F, Glimelius B et al: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308-317. 2002.
18. Saltz LB, Cox JV, Blanke C et al: CPT11 plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
19. Giacchetti S, Perpoint B, Zidani R et al: Phase III multicenter trial of oxaliplatin added of chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000.
20. Rougier P, Van CE, Bajetta E et al: Randomized trial of CPT11 versus fluorouracil continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998.
21. Aschele C, Debernardis D, Casazza S, Antonelli G et al: Immunohistochemical quantification of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17 (6): 1760-1770, 1999.
22. Curé H, Chevalier V, Adenis A, Tubiana-Mathieu N et al: Phase II trial of chronomodulated infusion of high-dose fluorouracil and 1-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol 20: 1175-1181, 2002.
23. De Gramont A, Vignoud J, Tournigand C et al: oxaliplatin with high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219, 1997.
24. Rougier P, Bugat R, Douillard JY et al: Phase II study of CPT11 in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pre-treated with fluorouracil-based chemotherapy. J Clin Oncol 15 (1): 251-260, 1997.
25. Twelves C: Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 38: 15-20, 2002.
26. Cox JV, Pazdur R, Thibault A, Maroun J et al: A phase III trial of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Am Soc Clin Oncol 18: (abs 1016), 1999.
27. Vanhoefer U, Mayer S, Harstrick A et al: Phase I study of capecitabine in combination with a weekly schedule of irinotecan (CPT-11) as first-line chemotherapy in metastatic colorectal cancer. Am Soc Clin Oncol 19: 272 (abs 1059), 2000.
28. Cassata A, Alù M, Beretta E et al: Capecitabine in combination with two schedule of irinotecan (CPT11) in advanced colorectal cancer: a pilot experience. Ann Oncol 11 (suppl 4): 45 (abs 192), 2000.
29. Diaz-Rubio E, Evans J, Tabernero J et al: Phase I study of capecitabine in combination with oxaliplatin in patients with advanced or metastatic solid tumors. Am Soc Clin Oncol 19: 272 (abs 1059), 2000.
30. Borner MM., Dietrich D, Stupp R, Morant R et al for the Swiss Group for Clinical Cancer Research. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20: 1759-1766, 2002.
31. Jordan K, Grothey A, Kellner O, Constantin C et al: Randomized phase II trial of capecitabine plus CPT11 versus capecitabine plus oxaliplatin as I line therapy in advanced colorectal cancer: results of an interim analysis. Am Soc Clin Oncol 21: 103 (abs 2225), 2002.
32. Borner M, Schsffski P, de Wit R, Caponigro F et al: A randomized crossover trial comparing oral UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer. Am Soc Clin Oncol 19: (abs 741), 2000.
33. Douillard J-Y, Hoff PM, Skillings JR, Eisenberg PD et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 (17): 3605-3616, 2002.
34. Carmichael J, Popiela T, Radstone D, Falk S et al: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer, J Clin Oncol 20 (17): 3617-3627, 2002.
35. Gunasekara NS and Faulds D: Ralitrexed: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs Aids Drug Evaluation 55: 423-435, 1998.
36. Comella P, De Vita F, De Lucia L, Lorusso V et al: Biweekly treatment with either CPT11 or tomudex followed by levo leucovorin modulated 5FU bolus in advanced colorectal carcinoma. Am Soc Clin Oncol 19: 257 (abs 998), 2000.
37. Douillard J, Michel P, Gamelin E, Conroy T et al: Ralitrexed plus oxaliplatin: an active combination for first line chemotherapy in patients with metastatic colorectal cancer. Am Soc Clin Oncol 19: 251 (abs 971), 2000.
38. Garcia MI, Gilles V, Louvet C, Defrance R et al: Bi-weekly irinotecan (CPT-11) combined with raltitrexed ('tomudex') treatment in heavily pre-treated patients with advanced colorectal cancer: A feasibility study. Am Soc Clin Oncol 19: 252 (abs 987), 2000.
39. Shimada Y, Yoshino M, Wakui A, Nakao I et al: Phase II study of CPT11, a new camptothecin derivative, in metastatic colorectal cancer. CPT11 Gastrointestinal Cancer Study Group. J Clin Oncol 11 (5): 909-913, 1993.
40. Fuchs CS, Hecht JR, Moore MR, Harker G et al: Phase III comparison of two CPT11 dosing regimens (weekly × 4 every-6-weeks versus every-3-weeks) in second line metastatic colorectal cancer therapy. Am Soc Clin Oncol 21: 129 (abs 514), 2002.
41. Cunningham D, Pyrhonen S, James RD, Punt CJ et al: Randomized trial of CPT11 plus best supportive care alone after fluorouracil failure for patients with metastatic colorectal cancers. Lancet 352: 1413-1418, 1998.
42. Schmitt C, Blijham G, Jolain B, Rougier P and Van Custem E: Medical care consumption in a phase III trial comparing CPT11 with infusional 5-fluorouracil (5FU) in patients with metastatic colorectal cancer after 5FU failure. Anticancer Drugs 10 (6): 617-623, 1999.
43. Cunningham D and Glimelius B: A phase III study of CPT11 versus best supportive care in patients with metastatic colorectal cancers who have failed 5-fluorouracil therapy. V 301 Study Group. Sem Oncol 26 (1 suppl5): 6-12, 1999.
44. Shimada Y, Rougier P and Pitot H: Efficacy of CPT11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 32 (suppl3): 13-17, 1996
45. Firvida JL, Irigoyen A, Vazquez-Estevez S, Diz P, Constenia M, Casal-Rubio J et al: Phase II study of CPT11 as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer 91 (4): 704-711, 2001.
46. Andre T, Louvet C, Maindrault-Goebel F, Couteau C et al: CPT11 (irinotecan) addition to bimonthly, high dose leucovorin and bolus and continuous infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35 (9): 1343-1347, 1999.
47. Vamvakas L, Kakolyris S, Kououssis C, Kandilis K et al: Irinotecan (CPT11) in combination with infusional 5-fluorouracil and leucovorin (De Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am J Clin Oncol 25 (1): 65-70, 2002.
48. Douillard JY: CPT11 and high dose fluorouracil/leucovorin for metastatic colorectal cancer. Oncology 14 (12 suppl14): 51-55, 2000.
49. Maindrault F, Louvet C, Carola C and de Gramont A: Leucovorin, 5-Fluorouracil infusion and CPT11 (FOLFIRI-3) in pretreated patients with metastatic colorectal cancer. Am Soc Clin Oncol 21: 165 (abs 658), 2002.
50. Van Cutsem E, Pozzo C, Starkhammar H, Dirix L et al: A phase II study of CPT11 alternated with five days bolus of 5-fluorouracil and leucovorin in first line chemotherapy of metastatic colorectal cancer. Ann Oncol 9 (11): 1199-1204, 1998.
51. Douillard JY, Cunnigham D, Roth AD, Navarro M et al: CPT11 combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355 (9209): 1041-1047, 2000.
52. Pozzo C, Basso M, Massidda B et al: A randomized phase III multicenter trial comparing irinotecan CPT11 alternating with bolus 5-fluorouracil + folinic acid to bolus 5-fluorouracil + folinic acid (Mayo Clinic) in first-line treatment of metastatic colorectal cancer. Am Soc Clin Oncol 21: 100 (abs 2213), 2002.
53. Cassidy J: Review of oxaliplatin: an active platinum agent in golorectal cancer. Int J Clin Pract 54 (6): 399-402, 2000.
54. Wein A, Riedel C, Bruckl W, Merkel S et al: Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 64 (2): 131-138, 2003.
55. Bismuth H, Adam R, Levi F, Farabos C et al: Resection of non resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224 (4): 509-520 1996.
56. Levi F, Zidani R, Brienza S et al: A multicenter phase II trial of intensified chronotherapy with oxaliplatin (1-OHP), 5-fluorouracil (5-FU) and folinic acid (LV) in patients (PTS) with previously untreated metastatic colorectal cancer (MMC). Cancer 85: 2532-2540, 1999.
57. Giacchetti S, Itzahaki M, Gruia G, Adam R et al: Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 (6): 663-669, 1999.
58. Adam R, Avisar E, Ariche A, Giacchetti S et al: Five-year survival following hepatic resection after neoadjuvant therapy for non-resectable colorectal. Ann Surg Oncol 8 (4): 347-353, 2001.
59. de Gramont A, Tournigand C, Louvet C, Andre T et al: Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD. Rev Med Interne 18 (10): 769-775, 1997.
60. Andre T, Louvet C, Raymond E, Tournigand C and de Gramont A: Bimonthly high dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX 3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 9 (11): 1251-1253, 1998.
61. Andre T, Bensamine MA, Louvet C, Francois E et al: Multicenter phase II study of bimonthly high dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. J Clin Oncol 17 (11): 3560-3568, 1999.
62. Maindrault-Goebel F, Louvet C, Andre T, Carola E et al: Oxaliplatin added to the simplify bimonthly leucovorin and 5-fluorouracil regimen as a second-line therapy for metastatic colorectal cancer (FOLFOX 6). GERCOR. Eur J Cancer 35 (9): 1338-1342, 1999.
63. Maindraudt-Goebel F, de Gramont A, Louvet C, Andre T et al: Evaluation of Oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5FU continuous infusion regimen (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11 (11): 1477-1483, 2000.
64. Mosconi S, Cascinu S, Zaniboni A, Catalano V et al: The value of oxaliplatin in combination with continuous infusion ± bolus 5FU and levo-folinic acid in metastatic colorectal progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract). Tumori 86 (6): 465-469, 2000.
65. Maindraudt-Goebel F, de Gramont A, Louvet C and Andre T: Oxaliplatin Oncology Multidisciplinary Research Group (GERCOR). High-dose intensity oxaliplatin added to the simplify bimonthly leucovorin and 5-fluorouracil regimen as a second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37 (8): 1000-1005, 2001.
66. Levi F, Zidani R, Misset JL et al: Randomized multicenter chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 350: 681-686, 1997.
67. Giacchetti S, Bjarnason GA, Garufi C, Canon N et al: First line infusion of 5-fluorouracil, leucovorin, oxaliplatin for metastatic colorectal cancer chronomodulated versus conventional delivery. a multicenter randomized trial of the EORTC chronotherapy group. Am Soc Clin Oncol 21: 104 (abs 2231), 2002.
68. Kouroussis C, Souglakos J, Kakolyris S, Mavroudis D et al: Oxaliplatin in combination with infusional 5-Fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 61 (1): 36-41, 2001.
69. Artru P, Taieb J, Tournigand C, Louvet C et al: FOLFOX7/FOLFIRI (MIROX) regimen as (neo)adjuvant chemotherapy for patients with resectable metastatic colorectal cancer: preliminary results. Am Soc Clin Oncol 21: 169 (abs 672), 2002.
70. Becquarn Y, Gamelin E, Coudert B, Negrier S et al: Randomized multicenter phase II study comparing a combination of 5FU and folinic acid and alternating CPT11 and oxaliplatin with oxaliplatin and CPT11 in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 19 (22): 4195-4201, 2001.
71. Kaechele V, Hartmann JT, Lutz MP, Ohl U et al: A phase II study of dose-dense CPT11 and oxaliplatin as 2nd line treatment in advanced colorectal cancer after pretreatment with 5-FU. Am Soc Clin Oncol 21: 110 (abs 2252), 2002.
72. Beretta E, Bajetta E, Di Bartolomeo M, Ferrario E et al: Combination of oxaliplatin (Oxa) and irinotecan (CPT11) in FU-resistant metastatic colorectal cancer. Am Soc Clin Oncol 21: 165 (abs 657), 2002.
73. Salud A, Saigi E, Cirera L, Batiste-Alentorn E et al: Phase II trial of CPT11 and oxaliplatin in 5FU-resistant advanced colorectal cancer (ACRC). Am Soc Clin Oncol 21: 171 (abs 681), 2002.
74. Goldberg RM, Morton RF, Sargeant DJ, Fuchs CS et al: Oxaliplatin or CPT11 + 5-Fluorouracil (5FU)/leucovorin (LV) or oxaliplatin + CPT11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup Study. Am Soc Clin Oncol 21: 128 (abs 511), 2002.
75. Roth AD, Seium Y, Ruhstaller T, Bauer J et al: Oxaliplatin (OXA) combined with irinotecan (CPT11) and 5FU/leucovorin (OCFL) in metastatic colorectal cancer (MCRC): a phase I-II study. Am Soc Clin Oncol 21: 143 (abs 570), 2002.
76. Calvo E, Cortes J, Rodriguez J, Fernandez-Hidalgo O et al: CPT11, oxaliplatin, and 5FU/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer 2 (2): 104-110, 2002.
77. Schalhorn A, Stauch M, Quietzsch D, Maubach P et al: CPT11 plus oxaliplatin versus CPT11 plus 5FU/folinic acid (FA) as first-line treatment in metastatic colorectal cancer (CRC): interim toxicity analysis of a randomized phase III trial. Am Soc Clin Oncol 21: 149 (abs 594), 2002.
78. Souglakos J, Athanasiadis A, Ginopoulos P, Giannakakis T et al: Oxaliplatin (L-OHP) combined with CPT11 (CPT11), leucovorin (LV) and 5-fluorouracil (5FU) (FOLFOXIRI) compared with CPT11, LV, and 5FU (FOLFIRI) as first-line treatment for metastatic colorectal cancer: preliminary safety and efficacy results of a multicenter randomized trial. Am Soc Clin Oncol 21: 153 (abs 608), 2002.
79. Comella P, Buzzi F, Iannelli A, Mancarela S et al: Oxaliplatin plus leucovorin/fluorouracil i.v. bolus (OXAFAFU) versus CPT11 plus leucovorin/fluorouracil i.v. bolus (IRIFAFU) as first-line treatment of advanced colorectal carcinoma (ACC): SICOG 0103 randomised study. Am Soc Clin Oncol 21: 162 (abs 645), 2002.
80. Scheithauer W, Kornek GV, Raderer M, Ulrich-Pur H et al: Randomized multicenter phase II trial of oxaliplatin plus CPT11 versus ralitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 20: 165-172, 2002.
81. Nakamoto T, Inagawa H, Nishizawa T, Honda T et al: Antitumor effects of isolated hypoxic hepatic perfusion (IHHP) with high-dose TNF against colonic liver metastases in a rat model. Anticancer Res 22 (4): 2455-2459, 2002.
82. Kim R, Yamaguchi Y and Toge T. Adjuvant therapy for colorectal carcinoma. Anticancer Res 22 (4): 2413-2418, 2002.
83. Cascinu S, Graziano F, Ferrau F, Catalano V et al: Ralitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 13 (5): 716-720, 2002.
84. Papamichael D: Prognostic role of angiogenesis in colorectal cancer. Anticancer Res 21 (6B): 4349-4353, 2001.
85. Thijssen MA, Swinkels DW, Ruers TJ and de Kok JB: Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res 22 (1A): 421-425, 2002.
86. Lechaux D, Gervais A, Dazord L, Eliat PA et al: Adoptive immunotherapy monitored by micro-MRI in experimental colorectal liver metastasis. Anticancer Res 22 (1A): 151-158, 2002.